TRANSDERMAL ADMINISTRATION OF THE DOPAMINE AGONIST N-0437 AND 7 ESTER PRODRUGS - COMPARISON WITH ORAL-ADMINISTRATION IN THE 6-OHDA TURNING MODEL

被引:10
作者
DENDAAS, I
TEPPER, PG
ROLLEMA, H
HORN, AS
机构
[1] University Centre for Pharmacy, State University of Groningen, AW Groningen, NL-9713
关键词
PRODRUGS; TRANSDERMAL; ORAL; 6-OHDA; N-0437; DOPAMINE AGONISTS;
D O I
10.1007/BF00175708
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The potent and selective D2-agonist N-0437 [2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin] undergoes considerable first-pass metabolism after oral administration due to glucuronidation of the phenolic group. In an attempt to improve its bioavailability, seven ester prodrugs of N-0437 were sythesized, i.e the acetyl-, propionyl-, isobutyryl-, pivaloyl-, 2-aminophenyl 2-methoxy-phenyl- and 2,4-dimethylphenyl-analogues. In vivo activities were assessed by measuring contralateral turning after transdermal administration of N-0437 and its prodrugs to rats with unilateral 6-OHDA lesions of the nigrostriatal pathway, From time-effect curves the area under the curve for separate time intervals was taken as a measure of dopaminergic activity during that interval. It was found that slowly hydrolyzing prodrugs, which are known to show an improved duration of action after oral administration, are devoid of activity after transdermal application. The acetyl-, the propionyl- and the isobutyryl analogues, which are prodrugs with a relatively high hydrolysis rate, were found to have interesting and promising profiles following transdermal application.
引用
收藏
页码:655 / 659
页数:5
相关论文
共 22 条
[1]  
BARRY BW, 1987, DRUG DELIVERY SYSTEM
[2]  
BUNDGAARD H, 1985, DESIGN PRODRUGS, P1
[3]  
BUNDGAARD H, 1984, CONTROLLED DRUG DELI, P179
[4]   PRODRUGS FOR DERMAL DELIVERY [J].
CHAN, SY ;
PO, ALW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (01) :1-16
[5]   THE ANTIPARKINSONIAN ACTIONS AND PHARMACOKINETICS OF TRANSDERMAL (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (+PHNO) - PRELIMINARY-RESULTS [J].
COLEMAN, RJ ;
LANGE, KW ;
QUINN, NP ;
LOPER, AE ;
BONDI, JV ;
HICHENS, M ;
STAHL, SM ;
MARSDEN, CD .
MOVEMENT DISORDERS, 1989, 4 (02) :129-138
[6]   IMPROVEMENT OF THE ORAL BIOAVAILABILITY OF THE SELECTIVE DOPAMINE AGONIST N-0437 IN RATS - THE INVITRO AND INVIVO ACTIVITY OF 8 ESTER PRODRUGS [J].
DENDAAS, I ;
TEPPER, PG ;
HORN, AS .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1990, 341 (03) :186-191
[7]   THE METABOLIC-FATE OF THE DOPAMINE AGONIST 2-(N-PROPYL-N-2-THIENYLETHYLAMINO)-5-HYDROXYTETRALIN IN RATS AFTER INTRAVENOUS AND ORAL-ADMINISTRATION .2. ISOLATION AND IDENTIFICATION OF METABOLITES [J].
GERDING, TK ;
DRENTH, BFH ;
DEZEEUW, RA ;
TEPPER, PG ;
HORN, AS .
XENOBIOTICA, 1990, 20 (05) :525-536
[8]  
HADGRAFT J, 1985, DESIGN PRODRUGS, P271
[9]  
HIGUCHI WI, 1983, TRANSDERMAL DELIVERY, V3, P44
[10]  
KONIG JFR, 1963, RAT BRAIN STEREOTAXI, V4